Clinical trials: Small Cell Lung Carcinoma
Non Small Cell Lung Cancer, Metastatic Lung Cancer
Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)
This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung.
- Conditions
- Non Small Cell Lung Cancer, Metastatic Lung Cancer, Lung Cancer
- Trial name
- VAPORIZE (NCT03198468)
- Testing
- Bronchoscopic Thermal Vapor Ablation
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Uptake Medical Technology, Inc.
NSCLC, Other Solid Tumors
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
This is a Phase 1/2 study of GB263T in participants with advanced NSCLC and other solid tumor. The study will consist of a dose-escalation and expansion stage to determine RP2D (Phase 1), and an extension stage (Phase 2) where…
- Trial name
- NCT05332574
- Testing
- GB263T
- Where
- 4 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Genor Biopharma Co., Ltd.
Non Small Cell Lung Cancer
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors
The goal of this observational study is to determine if liquid biopsies from patients with stage I non-small cell lung cancer (NSCLC) can add to the diagnosis of a small lung cancer, or can better detect recurrent lung cancer…
- Trial name
- SABR-DETECT (NCT05921474)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lung Cancer (NSCLC)
Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer
Early-stage lung cancer represents a clinical challenge that, when diagnosed promptly, offers high chances of cure through lobectomy and lymphadenectomy.
- Trial name
- NCT07790406
- Testing
- da Vinci Single Port
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
PDX Models From EGFR Mutant Tumors
A biospecimen collection study from individuals with EGFR mutant cancers resistant to EGFR TKIs or those harboring an Exon 20 insertion mutation.
- Trial name
- NCT03872440
- Where
- United States
- Sponsor
- Addario Lung Cancer Medical Institute
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment.
- Trial name
- NCT00732810
- Testing
- SCH 727965, Capecitabine, Erlotinib
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Overal Survival, Non-small Cell Lung Cancer
Bone Metastasis on the Survival of Gefitinib Effective Patients
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective…
- Trial name
- NCT03157310
- Testing
- Gefitinib
- Volunteers
- 265 people
- Sponsor
- Qilu Hospital of Shandong University
Ovarian Cancer, Head and Neck Cancer
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
- Conditions
- Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer
- Trial name
- NCT05001347
- Testing
- TJ004309
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- I-Mab Biopharma US Limited
Stage IV Non-small Cell Lung Cancer
KN046 in Patients With Advanced Non-small Cell Lung Cancer
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
- Trial name
- NCT03838848
- Testing
- KN046, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been…
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Trial name
- NCT01774578
- Testing
- Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine
- Where
- 24 sites in United States
- Volunteers
- 135 people
- Sponsor
- NewLink Genetics Corporation
Neoplasms, Metastatic Cancer
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
- Conditions
- Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor
- Trial name
- NCT03307785
- Testing
- Niraparib, TSR-042, Carboplatin-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tesaro, Inc.
Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence.
- Trial name
- NCT06406608
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Advanced or Metastatic NSCLC
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and…
- Trial name
- LOTOS (NCT05941897)
- Testing
- Ceralasertib, Durvalumab
- Where
- 8 sites in Russia
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Lung Cancer, Non Small Cell Lung Carcinoma
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung…
- Trial name
- NCT00111839
- Testing
- Pemetrexed, Matuzumab
- Where
- 58 sites in United States, Austria and 1 more
- Volunteers
- 150 people
- Sponsor
- EMD Serono
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival…
- Trial name
- NADIM-ADJUVANT (NCT04564157)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- 30 sites in Spain
- Volunteers
- 210 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer Adenocarcinoma
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
This study will be conducted in adult participants diagnosed with NSCLC who have been previously treated for a minimum of 12 weeks with any PD-1 or PD-L1 checkpoint inhibitor.
- Trial name
- NCT03696212
- Testing
- grapiprant and pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Arrys Therapeutics